Paediatric Castleman Disease: Diagnostic Challenges and Lessons from Two Rare Cases

Castleman disease (CD) is a rare and heterogeneous lymphoproliferative disorder that affects both children and adults, typically presenting in young to middle-aged individuals. It is classified clinically as unicentric Castleman disease (UCD), which typically affects a single lymph node region and is often of the hyaline vascular subtype, or multicentric Castleman disease (MCD), which involves multiple lymph node stations and systemic inflammation. MCD includes HHV‑8–associated MCD and idiopathic MCD (iMCD), each with distinct diagnostic and therapeutic profiles. CD can mimic various malignant, infectious, and autoimmune diseases, leading to frequent diagnostic challenges. Although paediatric cases are uncommon, they often exhibit overlapping clinical and histological features, necessitating a high index of suspicion for accurate diagnosis and management. Two rare paediatric cases of Castleman disease are reported, involving a 7-year-old and a 9-year-old male, each presenting with atypical symptoms and complex clinical profiles. The first case presented with progressive respiratory distress, cachexia, generalized lymphadenopathy, and a mediastinal mass initially suspected to be lymphoma. Although histopathology demonstrated hyaline vascular Castleman disease—a subtype typically seen in unicentric disease—the extent of lymphadenopathy and systemic compromise indicated a multicentric clinical behavior. Histopathology revealed hyaline vascular Castleman disease. The second case presented with prolonged fever, cough, pleural effusion, hepatosplenomegaly, nephropathy, and cardiac dysfunction. These widespread systemic abnormalities are more suggestive of multicentric Castleman disease (MCD), despite the hyaline vascular histologic findings. Extensive investigations excluded infectious and malignant causes, and lymph node biopsy confirmed hyaline vascular Castleman disease. Both cases required multidisciplinary evaluation and were subsequently referred for specialized tertiary management. Castleman disease, though rare in children, should be considered in cases of persistent lymphadenopathy and systemic illness unresponsive to conventional therapy. Early biopsy and histopathological confirmation remain essential for diagnosis, while timely referral and multidisciplinary management optimize outcomes. Increased awareness, improved diagnostic access, and expanded availability of immunomodulatory therapy are critical to improving prognosis in paediatric Castleman disease.

Castleman disease, hyaline vascular type, paediatric lymphoproliferative disorder, lymphadenopathy, histopathology.

1. Liu AY, Nabel CS, Finkelman BS, et al. Idiopathic multicentric Castleman’s disease: a systematic literature review. Lancet Haematol. 2016;3(4):e163–75. [Google Scholar] [Crossref]

2. Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646–57. [Google Scholar] [Crossref]

3. Chronowski GM, Ha CS, Wilder RB, et al. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer. 2001;92(3):670–6. [Google Scholar] [Crossref]

4. Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol. 2005;129(1):3–17. [Google Scholar] [Crossref]

5. Dispenzieri A, Armitage JO, Loe MJ, et al. The clinical spectrum of Castleman’s disease. Am J Hematol. 2012;87(11):997–1002. [Google Scholar] [Crossref]

6. Castleman B, Towne VW. Case records of the Massachusetts General Hospital. N Engl J Med. 1954; 250:1001–5. [Google Scholar] [Crossref]

7. Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020;135(16):1353–64. [Google Scholar] [Crossref]

8. Munshi N, Mehta P. Castleman disease: from bench to bedside. Blood Rev. 2015;29(5):333–43. [Google Scholar] [Crossref]

9. Fajgenbaum DC, Shilling D. Castleman disease pathogenesis. Hematol Oncol Clin North Am. 2018;32(1):39–54. [Google Scholar] [Crossref]

10. Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol. 2005;129(1):3–17. [Google Scholar] [Crossref]

11. Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman’s disease: a systematic review of 404 published cases. Ann Surg. 2012;255(4):677–84. [Google Scholar] [Crossref]

12. Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol. 2009;16(4):236–46. [Google Scholar] [Crossref]

13. Van Rhee F, Stone K, Szmania S, et al. International multicentric Castleman disease consensus treatment guidelines 2018. Blood. 2018;132(16):1797–808. [Google Scholar] [Crossref]

14. Oksenhendler E, Boutboul D, Fajgenbaum DC, et al. Multicentric Castleman disease: clinical and therapeutic perspectives. Expert Rev Hematol. 2018;11(7):549–63. [Google Scholar] [Crossref]

15. Soumerai JD, van Rhee F, Mehta J, et al. Clinical and histopathologic heterogeneity in pediatric Castleman disease. Pediatr Blood Cancer. 2020;67(4):e28123. [Google Scholar] [Crossref]

16. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627–32. [Google Scholar] [Crossref]

17. Munshi N, Mehta P. Castleman disease: from bench to bedside. Blood Rev. 2015;29(5):333–43. [Google Scholar] [Crossref]

18. Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020;135(16):1353–64. [Google Scholar] [Crossref]

19. Van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman’s disease: a randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15(9):966–74. [Google Scholar] [Crossref]